GLPG CAR T-cell therapy

drug_type

RELEVANT_DRUG

intervention_type

Cellular therapy (CAR T cells)

drug_description

Gene-modified autologous T-cell immunotherapy using an integrating lentiviral vector to express a chimeric antigen receptor (CAR). The CAR targets a tumor-associated surface antigen (unspecified), triggering CD3ζ and costimulatory signaling to activate T cells, drive clonal expansion, cytokine release, and antigen-specific cytotoxicity; persistence and safety (e.g., replication-competent lentivirus, insertional events) are monitored.

nci_thesaurus_definition

NCI thesaurus definition not available.

drug_mesh_term

Chimeric Antigen Receptor T-Cell Therapy

drug_category

CAR T

drug_class

Cellular Therapy

drug_delivery_route

Intravenous

drug_mechanism_of_action

Autologous T cells are gene-modified with an integrating lentiviral vector to express a chimeric antigen receptor that recognizes a tumor-associated surface antigen. Antigen binding triggers TCR-independent CD3ζ and costimulatory signaling, leading to T-cell activation, clonal expansion, cytokine release, and antigen-specific cytotoxic killing; persistence and safety (e.g., replication-competent lentivirus, insertional events) are monitored.

drug_name

GLPG CAR T-cell therapy

nct_id_drug_ref

NCT06652633